Director of Interventional Radiology
Professor of Radiology, Oncology, and Surgery
Dr. Geschwind is an Professor of Radiology, Oncology, and Surgery at the Johns Hopkins University School of Medicine and the Director of Interventional Radiology at The Johns Hopkins Hospital. Originally from Paris, France, Dr. Geschwind pursued his undergraduate studies both at the University of Paris (France) and at the University of Pennsylvania in Philadelphia before receiving his Doctorate Degree (M.D.) in 1991 from the Boston University School of Medicine in Boston. After an internship in Boston, Dr. Geschwind moved to San Francisco where he completed his residency training in Diagnostic Radiology at the University of California, San Francisco in 1996. While at UCSF, he worked under the direction of Dr. Charles Higgins as an NIH fellow and a Scholar in the Radiology Department. The focus of his research was on cardiac MR imaging, more specifically the use of MR contrast media in the assessment of myocardial viability. He then pursued his training in Cardiovascular and Interventional Radiology at Johns Hopkins before joining the faculty in 1998. He was promoted to the rank of Professor in 2008 and is the Director of Cardiovascular and Interventional Radiology.
Dr. Geschwind is the author or co-author of over 140 published manuscripts and abstracts primarily on subjects dealing with cardiac MRI and oncology. He is also the recipient of numerous national and international awards and grants for his research in the field of cardiac MRI and liver cancer. He has lectured nationally and throughout the world on the clinical management of patients with liver cancer. His primary research interests include finding new therapies for liver cancer, assessing tumor response after therapy using functional MR imaging, and investigating new drug delivery systems for loco-regional cancer therapy. Along with colleagues from the Department of Biological Chemistry, he has focused his research further into developing a new therapeutic approach for liver cancer using drugs specifically designed to block tumor metabolism in cancer cells. His primary clinical interests include treatment of hepatic and other malignancies as well as biliary tract diseases.
Dr. Geschwind is an active member of the American Association for Cancer Research, the American Society of Clinical Oncology, the American Roentgen Ray Society, the Radiology Society of North America, the Society of Interventional Radiology (SIR), the American Heart Association, and the Cardiovascular and Interventional Society of Europe.
See also:
Liver chemoembolization
